Symbols

URGN

UroGen Pharma·NASDAQ

--(--)

URGN fundamentals

URGN Q4 2025 Earnings

UroGen Pharma (URGN) released its earnings on Mar 2, 2026: revenue was 37.84M (YoY +54.03%), missed estimates; EPS was -0.54 (YoY +32.50%), missed estimates.

Revenue / YoY

37.84M

+54.03%

EPS / YoY

-0.54

+32.50%

Report date

Mar 2, 2026

URGN Earnings Call Summary for Q4,2025

ZUSDURI Launch Acceleration: Early 2026 metrics surpass JELMYTO's launch, with 838 activated sites and 102 prescribers. Peak revenue potential >$1 billion.
Pipeline Momentum: UGN-103 Phase III data supports 2027 FDA approval; UGN-104 enrollment on track for 2026 completion. UGN-501 IND submission expected in 2026.
Financial Strength: $250 million debt refinancing reduces interest costs and extends repayment, supporting disciplined capital allocation.
JELMYTO Sustainability: 2025 revenue $94 million reflects steady demand, with cross-promotion opportunities driving long-term growth.

Earnings

EPS

Revenue

Revenue & Expenses

URGN has released its 2025 Q4 earnings report, with revenue of 37.84M, reflecting a YoY change of 54.03%, and net profit of -26.36M, showing a YoY change of 29.72%. The Sankey diagram below clearly presents URGN's revenue sources and cost distribution.

Key Indicators

UroGen Pharma (URGN) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

UroGen Pharma (URGN)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

UroGen Pharma (URGN)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

UroGen Pharma (URGN)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown